Preventive Effect of Rifampicin on Dementia
Project/Area Number |
18K07488
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 52010:General internal medicine-related
|
Research Institution | Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology |
Principal Investigator |
Kameyama Masashi 地方独立行政法人東京都健康長寿医療センター(東京都健康長寿医療センター研究所), 東京都健康長寿医療センター研究所, 研究員 (40773445)
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2020)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | アルツハイマー病 / 認知症 / 人工知能 / リファンピシン / PET / アミロイド / タウ / アミロイドβ |
Outline of Final Research Achievements |
Distinguishing Alzheimer's disease (AD) from other dementia is crucial for the future use of rifampicin. We have tried comparison of medial temporal lobe atrophy by MRI and amyloid PET for AD discrimination, distinguishing DLB, AD, and normal by perfusion SPECT and FDG PET images with AI, fractal analysis of Dopamine transporter SPECT, proposal of a new quantification method of cerebral blood flow, examination of reference region of amyloid PET by simulation, detection of degeneration by [18F]THK5351 PET, and screening of cognitive decline by facial complexion using AI.
|
Academic Significance and Societal Importance of the Research Achievements |
顔写真をAIが認知機能低下を見分けたことは、将来、AIを用いて顔で認知機能低下をスクリーニングすることができるようになるかもしれないという可能性を示しており、新聞などに取り上げられ、大きな反響があった。
|
Report
(4 results)
Research Products
(69 results)
-
[Journal Article] Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study2021
Author(s)
Matsuda H, Ito K , Ishii K, Shimosegawa E, Okazawa H, Mishina M, Mizumura S, Ishii K, Okita K, Shigemoto Y, Kato T, Takenaka A, Kaida H, Hanaoka K, Matsunaga K, Hatazawa J, Ikawa M, Tsujikawa T, Morooka M, Ishibashi K, Kameyama M, Yamao T, Miwa K, Ogawa M, Sato N.
-
Journal Title
Frontiers in Neurology
Volume: 11
Pages: 578753-578753
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline?2019
Author(s)
Funaki K, Nakajima S, Noda Y, Wake T, Ito D, Yamagata B, Yoshizaki T, Kameyama M, Nakahara T, Murakami K, Jinzaki M, Mimura M, Tabuchi H.
-
Journal Title
Psychogeriatrics
Volume: AOP
Issue: 4
Pages: 325-332
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] Occult mucin-producing urothelial-type adenocarcinoma of the prostate with elevated serum levels of carcinoembryonic antigen and carbohydrate antigen 19-9: Report of an autopsy-proven case2018
Author(s)
Nonaka K, Matsuda Y, Kakizaki M, Takakuma S, Matsubara T, Murayama S, Ishiwata T, Kameyama M, Ogura K, Kobayashi S, Arai T
-
Journal Title
Urol Case Rep
Volume: 23
Pages: 6-9
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Disclosure of Amyloid Status for Risk of Alzheimer’s Disease to Cognitively Normal Persons with Subjective Cognitive Decline2018
Author(s)
Taisei Wake, Hajime Tabuchi, Kei Funaki, Daisuke Ito, Bun Yamagata, Takahito Yoshizaki, Masashi Kameyama, Tadaki Nakahara, Koji Murakami, Masahiro Jinzaki, Haruo Yoshimasu, Iori Tanahashi, Hiromi Shimazaki, Masaru Mimura.
Organizer
Alzheimer’s Association International Conference
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-